European Medicines Agency (EMA): Guideline on Quality, Non-Clinical and Clinical Requirements for Investigational Advanced Therapy Medicinal Products in Clinical Trials

EMA 2025 Guideline on Investigational Advanced Therapy Medicinal Products (ATMPs)

In 2025, the European Medicines Agency (EMA) finalized updated guidance outlining regulatory expectations for the development of investigational Advanced Therapy Medicinal Products (ATMPs) in clinical trials within the European Union. The guideline provides an integrated framework covering quality (CMC), non-clinical, and clinical requirements for gene therapies, somatic cell therapies, and tissue-engineered products.

‍

This document reflects the increasing scientific complexity of advanced therapies and the need for consistent, risk-based regulatory standards that support innovation while maintaining patient safety and product integrity.

‍

Scope and Purpose

The guideline is intended to assist sponsors and developers preparing ATMPs for clinical investigation. It clarifies what data should be generated and how it should be structured to support clinical trial authorization applications in EU Member States.

‍

It applies to:

• Gene therapy medicinal products
• Somatic cell therapy medicinal products
• Tissue-engineered products
• Combined ATMPs

‍

The guidance promotes early dialogue with regulatory authorities and encourages development strategies tailored to the specific risks and characteristics of each product.

‍

Quality (CMC) Expectations

The guideline emphasizes robust control over manufacturing processes and product characterization. Key themes include:

• Detailed description and control of starting materials and raw materials
• Characterization of active substances, including biological properties and potency
• Manufacturing consistency and process validation strategies
• Stability data to support shelf-life and storage conditions
• Comparability considerations when manufacturing processes evolve

‍

Given the inherent variability of living cells and gene-modified products, the guideline supports a risk-based approach to defining critical quality attributes and control strategies.

‍

Non-Clinical Requirements

For non-clinical development, the guideline outlines expectations for safety and proof-of-concept data generated through in vitro and in vivo models. It recognizes that traditional pharmacology and toxicology paradigms may not always apply directly to ATMPs.

‍

Key considerations include:

• Biodistribution and persistence studies
• Tumorigenicity risk assessment
• Immunogenicity evaluation
• Dose justification strategies
• Selection of relevant animal models

‍

The document acknowledges that scientific justification may replace certain traditional testing approaches where appropriate models are not available.

‍

Clinical Development Considerations

For clinical trials, the guidance addresses:

• Dose selection and escalation strategies
• Patient population justification
• Risk mitigation and monitoring plans
• Long-term follow-up for delayed adverse events
• Data collection to support eventual marketing authorization

‍

Because ATMPs may present unique or delayed safety concerns, the guideline highlights the importance of pharmacovigilance planning and post-trial monitoring.

‍

Risk-Based and Adaptive Approach

A central theme of the 2025 guidance is flexibility grounded in scientific rationale. The EMA encourages:

• Case-by-case evaluation
• Early regulatory consultation
• Adaptive development pathways
• Justified deviations from standard testing frameworks when scientifically appropriate

‍

This approach reflects the evolving nature of gene and cell-based technologies.

‍

Regulatory Context

The development of advanced therapy medicinal products (ATMPs) is guided by defined regulatory standards. Familiarity with guidelines such as this supports the academic and professional preparation of individuals pursuing careers in the life sciences.

‍

Access the Full Guideline

Read the full EMA guideline here:
https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-non-clinical-clinical-requirements-investigational-advanced-therapy-medicinal-products-clinical-trials_en.pdf?

‍

Reference:

European Medicines Agency. (2025). Guideline on quality, non-clinical and clinical requirements for investigational advanced therapy medicinal products in clinical trials (EMA/CAT/22473/2025). https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-non-clinical-clinical-requirements-investigational-advanced-therapy-medicinal-products-clinical-trials_en.pdf